Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > mdgl downgrade

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Jul 08, 2022 10:39am

90 Views

Post# 34810870

RE:mdgl downgrade

The timing of this seems completely arbitrary.

palinc2000 wrote:

08:48 AM EDT, 07/08/2022 (MT Newswires) -- B Riley Securities downgrades Madrigal Pharmaceuticals (MDGL) to neutral from buy due to relatively lowered conviction in the Phase III MAESTRO-NASH study biopsy readout expected in Q4 to support regulatory approvals and successful commercialization.

The firm, in a Friday research report, also lowered the price target to $75 from $131, reflecting an incrementally lower probability of technical and regulatory success for resmetirom in NASH, and modest OpEx spend forecasted, and slight delay in market entry.

The firm also reaffirmed its positive view on the company's best-in-industry execution. Madrigal Pharmaceuticals has an average rating of outperform and price targets ranging from $75 to $203, according to analysts polled by Capital IQ.